Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04740671 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD
A Phase 3 study, sponsored by Shanghai Henlius Biotech.
- Completed
- Registry status
- Phase 3
- Development phase
- 410
- Enrollment target
NCT04740671 is a Phase 3 study that has completed, run by Shanghai Henlius Biotech. The registered enrollment target is 410 participants.
The verdict
NCT04740671, a Phase 3 study, has completed, sponsored by Shanghai Henlius Biotech.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 410 participants
- Enrollment target
Study Summary
This study will compare the efficacy and safety of HLX04-O administered by intravitreal injection (IVT) with ranibizumab in patients with active wAMD.
Interventions
- DRUG ranibizumab
- DRUG HLX04-O
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 410 participants |
| Start Date | 2021-07-01 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04740671
The ClinicalTrials.gov registry entry for NCT04740671 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 410 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shanghai Henlius Biotech, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ranibizumab is the first listed.
NCT04740671 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04740671 about?
NCT04740671 is a clinical study titled "A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD". This study will compare the efficacy and safety of HLX04-O administered by intravitreal injection (IVT) with ranibizumab in patients with active wAMD.
What is the current status of trial NCT04740671?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 410 participants. The study started on 2021-07-01. Estimated completion is 2024-12-31.
What interventions are being tested in trial NCT04740671?
The interventions under investigation include: ranibizumab (DRUG), HLX04-O (DRUG).
Who is sponsoring clinical trial NCT04740671?
This trial is sponsored by Shanghai Henlius Biotech, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.